Pfizer and BioNTech launch trial of Omicron-targeted Covid vaccine
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
FRIDAY, MAY 20, 2022
FRIDAY, MAY 20, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Pfizer and BioNTech launch trial of Omicron-targeted Covid vaccine

Coronavirus chronicle

Reuters
26 January, 2022, 08:40 am
Last modified: 26 January, 2022, 08:43 am

Related News

  • China Junshi's potential Covid drug shows promise in small trial
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • Shanghai achieves 'zero Covid' status but normal life is weeks away
  • N Korea mobilises army, steps up tracing amid Covid wave

Pfizer and BioNTech launch trial of Omicron-targeted Covid vaccine

The companies plan to study the safety and tolerability of the shots in the more than 1,400 people who will be enrolled in the trial

Reuters
26 January, 2022, 08:40 am
Last modified: 26 January, 2022, 08:43 am
A doctor shows vials of Biontech-Pfizer's Comirnaty vaccine against Covid-19 at the Institute for Health and Food Safety of Zenica, Bosnia and Herzegovina, December 16, 2021. Photo :Reuters
A doctor shows vials of Biontech-Pfizer's Comirnaty vaccine against Covid-19 at the Institute for Health and Food Safety of Zenica, Bosnia and Herzegovina, December 16, 2021. Photo :Reuters

Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the Covid-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.

Banking on volunteers in the United States, the companies plan to test the immune response generated by the Omicron-based vaccine both as a three-shot regimen in unvaccinated people and as a booster shot for people who already received two doses of their original vaccine.

They are also testing a fourth dose of the current vaccine against a fourth dose of the Omicron-based vaccine in people who received a third dose of the Pfizer/BioNTech vaccine three to six months earlier.

The companies plan to study the safety and tolerability of the shots in the more than 1,400 people who will be enrolled in the trial.

"While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," Pfizer's head of vaccine research and development, Kathrin Jansen, said in a statement.

Depending on the amount of clinical trial data required by regulators, it may not be possible to realize a current plan to launch an Omicron-targeting vaccine by the end of March, BioNTech said.

Pfizer has said that two doses of the original vaccine may not be sufficient to protect against infection from Omicron, and that protection against hospitalizations and deaths may be waning.

Still, the US Centers for Disease Control and Prevention says a third dose of an mRNA vaccine like the Pfizer/BioNTech vaccine has provided 90% protection against hospitalization due to Covid-19.

Some countries have already started offering additional booster doses, but a recent study from Israel showed that while a fourth dose of an mRNA vaccine boosted antibodies, the level was not high enough to prevent Omicron infection.

DATA The European Medicines Agency (EMA) said on Friday that international regulators want data from clinical studies like the one being done by Pfizer and BioNTech before approval of a new vaccine.

EMA said these studies should show that the new vaccines elicit more neutralising antibodies in the blood than current vaccines and might also protect against new variants of concern.

BioNTech declined to comment on what type of data it was asked to file with regulators.

It said an analysis of antibodies elicited by its Omicron-targeted booster should help answer whether shots will be needed that address more than one variant at a time. It hopes to show the antibodies neutralise a spectrum of variants.

Still, some scientists question whether any change is currently needed.

"The goal of this vaccine is to protect against serious illness," said Dr. Paul Offit, an infectious disease expert at the University of Pennsylvania. "To date, these vaccines do that, including protection against Omicron."

Top News / World+Biz

Pfizer / BionTech / omicron / Covid

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • US growth seen outpacing China’s for first time since 1976
    US growth seen outpacing China’s for first time since 1976
  • Students suffer over costlier food at public university canteens
    Students suffer over costlier food at public university canteens
  • A worker displays grains of wheat at a mill in Beirut, Lebanon, March 1, 2022. REUTERS/Mohamed Azakir/File Photo
    Russia can offer 25 mln tonnes of grain for export starting on 1 Aug: UN envoy

MOST VIEWED

  • Ryu Yong Chol, an official at North Korea's state emergency epidemic prevention headquarters, speaks during a daily coronavirus program on state-run television KRT, in this still image obtained from KRT footage released on May 20, 2022. REUTERS TV/KRT via REUTERS
    North Korea's Dr Fauci? Health official emerges as face of Covid campaign
  • Workers in protective suit spray disinfectant at a community, during the lockdown to curb the spread of the coronavirus disease (COVID-19) in Shanghai, China, April 5, 2022. REUTERS/Aly Song
    Shanghai detects new infections after five days of 'zero Covid'
  • Volunteers carry out temperature screening during an anti-virus campaign in Pyongyang, North Korea in this image released by North Korea's Korean Central News Agency (KCNA) on March 4, 2020. KCNA via REUTERS/File Photo
    North Korea hails 'good results' on Covid as fever cases pass 2 million
  • Medical staff members check the temperature of people as they enter at Capital Airport, following an outbreak of Covid-19, in Beijing, China, 5 November, 2020. Photo: Reuters
    China relaxes some Covid test rules for US, other travellers
  • Representational image.
    China Junshi's potential Covid drug shows promise in small trial
  • A woman wearing protective mask walks at a sidewalk near business district in Jakarta, Indonesia March 2, 2020. REUTERS/Willy Kurniawan/Files
    Indonesia to drop outdoor mask mandate as Covid-19 infections drop

Related News

  • China Junshi's potential Covid drug shows promise in small trial
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • Shanghai achieves 'zero Covid' status but normal life is weeks away
  • N Korea mobilises army, steps up tracing amid Covid wave

Features

Mohammad (Mejbah) Mejbahuddin, Former Senior Secretary, Economic Relations Division (ERD), Ministry of Finance, Government of Bangladesh. TBS Sketch

‘No project is being delayed too long at the moment’

3h | Panorama
Dr Shamsul Hoque, Professor, Civil Engineering, BUET. TBS Sketch

‘Planning commission only in the name, there are no planners’ 

3h | Panorama
Masrur Reaz. TBS Sketch

‘To ensure accountability, contract financing should be based on ‘performance based payments’

3h | Panorama
Professor Mustafizur Rahman. Illustration: TBS

Project delays and escalating costs are driven by frequent revisions and lack of good governance

6h | Panorama

More Videos from TBS

Ways to retain body fragrance

Ways to retain body fragrance

4h | Videos
Gazipur restaurant that serves 150 food items

Gazipur restaurant that serves 150 food items

8h | Videos
How to prepare for a job

How to prepare for a job

9h | Videos
Putin's strategies to face Nato

Putin's strategies to face Nato

21h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

3
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

4
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

5
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

6
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab